S. 1695 (110th): Biologics Price Competition and Innovation Act of 2007

Jun 26, 2007 (110th Congress, 2007–2009)
Died (Reported by Committee)
Edward “Ted” Kennedy
Senator from Massachusetts
Read Text »
Last Updated
Nov 19, 2008
88 pages

This bill was introduced on June 27, 2007, in a previous session of Congress, but was not enacted.

Introduced Jun 26, 2007
Referred to Committee Jun 26, 2007
Reported by Committee Jun 27, 2007
Full Title

A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes.


No summaries available.

4 cosponsors (2D, 2R) (show)

Senate Health, Education, Labor, and Pensions

The committee chair determines whether a bill will move past the committee stage.

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.


Get a bill status widget for your website »


Click a format for a citation suggestion:


S. stands for Senate bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

11/19/2008--Reported to Senate amended.
Biologics Price Competition and Innovation Act of 2007 - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).
Sets forth application requirements, including that the application demonstrate that:
(1) the biological is biosimilar to a reference product based upon data derived from studies;
(2) the biological product and reference product utilize the same mechanism of action; and
(3) the route of administration, the dosage form, and the strength of the biological product are the same as those of the reference product.
Allows an application to include information demonstrating that the biological product is interchangeable with the reference product.
Requires the Secretary of Health and Human Services to license the biological product if the information submitted in the application is sufficient to show that the biological product is biosimilar to or interchangeable with the reference product.
Allows products to be determined to be interchangeable if: (1) the biological product is biosimilar to the reference product and can be expected to produce the same clinical result as the reference product in any given patient; and (2) the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch.
Prohibits a biological product from being evaluated against more than one reference product.
Prohibits the Secretary from determining that a second or subsequent biological product is interchangeable with a reference product for any condition of use for specified periods based on the marketing of, and the presence or status of litigation involving, the first biosimilar biological product deemed interchangeable with the same reference product.
Prohibits approval of an application under this Act from being made effective until 12 years after the reference product was first licensed.
Authorizes the Secretary to issue guidance with respect to the licensure of a biological product after public comment.
Requires the Secretary to establish a process through which the public may provide the Secretary with input regarding priorities for issuing guidance.
Sets forth requirements for any product class-specific guidance that may be issued by the Secretary, including that such guidance include a description of the criteria that the Secretary will use to determine whether a biological product is highly similar to or interchangeable with a reference product in such product class.
Allows the Secretary to indicate in a guidance document that the science and experience with respect to a product or product class does not allow approval of an application for a license under this Act.
Sets forth provisions governing the exchange of confidential information related to patents for biological products. Requires confidential information to be used for the sole and exclusive purpose of determining whether a claim of patent infringement could reasonably be brought against the biosimilar biological product. Deems a disclosure of any confidential information in violation of this Act to cause the applicant to suffer irreparable harm for which there is no adequate legal remedy.
Requires good faith negotiations between the reference product sponsor and an applicant under this Act.
Sets forth provisions regarding patent infringement lawsuits, including the time frame for a reference product sponsor to bring an action for patent infringement.
Requires the Secretary to: (1) develop recommendations with respect to the goals for the review process of biosimilar biological product applications; (2) collect and evaluate data regarding the cost of reviewing such applications; and (3) determine whether to alter the user fee applicable to such applications.
Establishes the Biological Product Savings Fund in the Treasury to be funded with savings to the federal government as a result of the enactment of this Act and to be expended on activities authorized under the Public Health Service Act.
Directs the Comptroller General to study and report to Congress on: (1) the extent to which pediatric studies of biological products are required under the Federal Food, Drug, and Cosmetic Act; and (2) any pediatric needs not being met under existing authority.
Extends the time frame for a sponsor to have market exclusivity for a biological product designated for a rare disease or condition.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of S. 1695 (110th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus